Predictive value of clinical and 18F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma.

Aim of this study was to validate the prognostic impact of clinical parameters and baseline 18F-FDG-PET/CT derived textural features to predict histopathologic response and survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiation (nCRT) and surgery. Between 2005 and 2014, 38 ESCC were treated with nCRT and surgery. For all patients, the 18F-FDG-PET-derived parameters metabolic tumor volume (MTV), SUVmax, contrast and busyness were calculated for the primary tumor using a SUV-threshold of 3. The parameter uniformity was calculated using contrast-enhanced computed tomography. Based on histopathological response to nCRT, patients were classified as good responders (< 10% residual tumor) (R) or non-responders (≥ 10% residual tumor) (NR). Regression analyses were used to analyse the association of clinical parameters and imaging parameters with treatment response and overall survival (OS). Good response to nCRT was seen in 27 patients (71.1%) and non-response was seen in 11 patients (28.9%). Grading was the only parameter predicting response to nCRT (Odds Ratio (OR) = 0.188, 95% CI: 0.040-0.883; p = 0.034). No association with histopathologic treatment response was seen for any of the evaluated imaging parameters including SUVmax, MTV, busyness, contrast and uniformity. Using multivariate Cox-regression analysis, the heterogeneity parameters busyness (Hazard Ratio (HR) = 1.424, 95% CI: 1.044-1.943; p = 0.026) and contrast (HR = 6.678, 95% CI: 1.969-22.643; p = 0.002) were independently associated with OS, while no independent association with OS was seen for SUVmax and MTV. In patients with ESCC undergoing nCRT and surgery, baseline 18F-FDG-PET/CT derived parameters could not predict histopathologic response to nCRT. However, the PET/CT derived features busyness and contrast were independently associated with OS and should be further investigated

Die alte Heimat Hackelsdorf und Ochsengraben an der oberen hohen Elbe

Mit dem Erscheinen des noch ausstehenden 9. Bandes unserer Ortsbuch-Reihe, der die zwischen Spindelmühle und Oberhohenelbe gelegenen Riesengebirgsgemeinden Hackelsdorf und Ochsengraben behandelt, ist das gesamte Gebiet der oberen hohen Elbe, von Spindelmühle bis einschließlich Oberhohenelbe, durch Ortsbücher abgedeckt. [... aus dem Geleitwort

Die alte Heimat Hackelsdorf und Ochsengraben an der oberen hohen Elbe

Mit dem Erscheinen des noch ausstehenden 9. Bandes unserer Ortsbuch-Reihe, der die zwischen Spindelmühle und Oberhohenelbe gelegenen Riesengebirgsgemeinden Hackelsdorf und Ochsengraben behandelt, ist das gesamte Gebiet der oberen hohen Elbe, von Spindelmühle bis einschließlich Oberhohenelbe, durch Ortsbücher abgedeckt. [... aus dem Geleitwort

Precision molecular spectroscopy for ground state transfer of molecular quantum gases

One possibility for the creation of ultracold, high-phase-space-density quantum gases of molecules in the rovibrational ground state relies on first associating weakly-bound molecules from quantum-degenerate atomic gases on a Feshbach resonance and then transfering the molecules via several steps of coherent two-photon stimulated Raman adiabatic passage (STIRAP) into the rovibronic ground state. Here, in ultracold samples of Cs_2 Feshbach molecules produced out of ultracold samples of Cs atoms, we observe several optical transitions to deeply bound rovibrational levels of the excited 0_u^+ molecular potentials with high resolution. At least one of these transitions, although rather weak, allows efficient STIRAP transfer into the deeply bound vibrational level |v=73> of the singlet X ^1Sigma_g^+ ground state potential, as recently demonstrated. From this level, the rovibrational ground state level |v=0, J=0> can be reached with one more transfer step. In total, our results show that coherent ground state transfer for Cs_2 is possible using a maximum of two successive two-photon processes or one single four-photon STIRAP process.Comment: 6 figures, 1 tabl

Quantum Gas of Deeply Bound Ground State Molecules

We create an ultracold dense quantum gas of ground state molecules bound by more than 1000 wavenumbers by stimulated two-photon transfer of molecules associated on a Feshbach resonance from a Bose-Einstein condensate of cesium atoms. The transfer efficiency exceeds 80%. In the process, the initial loose, long-range electrostatic bond of the Feshbach molecule is coherently transformed into a tight chemical bond. We demonstrate coherence of the transfer in a Ramsey-type experiment and show that the molecular sample is not heated during the transfer. Our results show that the preparation of a quantum gas of molecules in arbitrary rovibrational states is possible and that the creation of a Bose-Einstein condensate of molecules in their rovibronic ground state is within reach.Comment: 4 figure

Exports and Productivity: Comparable Evidence for 14 Countries

We use comparable micro level panel data for 14 countries and a set of identically specified empirical models to investigate the relationship between exports and productivity. Our overall results are in line with the big picture that is by now familiar from the literature: Exporters are more productive than non-exporters when observed and unobserved heterogeneity are controlled for, and these exporter productivity premia tend to increase with the share of exports in total sales; there is strong evidence in favour of self-selection of more productive firms into export markets, but nearly no evidence in favour of the learning-by-exporting hypothesis. We document that the exporter premia differ considerably across countries in identically specified empirical models. In a meta-analysis of our results we find that countries that are more open and have more effective government report higher productivity premia. However, the level of development per se does not appear to be an explanation for the observed cross-country differences.exports; productivity; micro data; international comparison

Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus.

Specific differences in signaling and antiviral properties between the different Lambda-interferons, a novel group of interferons composed of IL-28A, IL-28B and IL-29, are currently unknown. This is the first study comparatively investigating the transcriptome and the antiviral properties of the Lambda-interferons IL-28A and IL-29. Expression studies were performed by microarray analysis, quantitative PCR (qPCR), reporter gene assays and immunoluminometric assays. Signaling was analyzed by Western blot. HCV replication was measured in Huh-7 cells expressing subgenomic HCV replicon. All hepatic cell lines investigated as well as primary hepatocytes expressed both IFN-λ receptor subunits IL-10R2 and IFN-λR1. Both, IL-28A and IL-29 activated STAT1 signaling. As revealed by microarray analysis, similar genes were induced by both cytokines in Huh-7 cells (IL-28A: 117 genes; IL-29: 111 genes), many of them playing a role in antiviral immunity. However, only IL-28A was able to significantly down-regulate gene expression (n = 272 down-regulated genes). Both cytokines significantly decreased HCV replication in Huh-7 cells. In comparison to liver biopsies of patients with non-viral liver disease, liver biopsies of patients with HCV showed significantly increased mRNA expression of IL-28A and IL-29. Moreover, IL-28A serum protein levels were elevated in HCV patients. In a murine model of viral hepatitis, IL-28 expression was significantly increased. IL-28A and IL-29 are up-regulated in HCV patients and are similarly effective in inducing antiviral genes and inhibiting HCV replication. In contrast to IL-29, IL-28A is a potent gene repressor. Both IFN-λs may have therapeutic potential in the treatment of chronic HCV

Thematische Bereiche: die Arbeitsgemeinschaften

Die Arbeitsgemeinschaft der Einrichtungen für Weiterbildung an Hochschulen (AG-E) (Karla Kamps-Haller/Bernhard Christmann/Helmut Vogt) Zur Entstehungsgeschichte der Arbeitsgemeinschaft für das Fernstudium an Hochschulen (AG-F) (Burkhard Lehmann) Bundesarbeitsgemeinschaft Wissenschaftliche Weiterbildung für Ältere (BAG WiWA) (Thomas Bertram/Silvia Dabo-Cruz/Karin Pauls/Michael Vesper) Der Artikel beschreibt ihre Entstehungsgeschichte und die Entwicklungsschritte beim Zusammenschluss mit der DGWF und ihrer Vorläuferorganisation. Dabei liegt ein Schwerpunkt auf neuen Zielgruppenanalysen und Forschungsfragen, mit denen zukünftig belastbare empirische Daten zur Bildung Älterer erhoben werden können. Abschließend werden die künftigen Herausforderungen für die BAG WiWA skizziert. Profilbildung und Professionalisierung durch Forschung. Die Arbeitsgemeinschaft Forschung (Wolfgang Jütte/Maria Kondratjuk/Mandy Schulze) Der Beitrag fasst die Zielsetzungen, die Aktivitäten und Aufgaben der Arbeitsgruppe zusammen. Dabei wird vor allem auf das jährliche Forschungsforum als offenes Diskussionsformat mit Werkstattcharakter eingegangen

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

BACKGROUND: Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer. METHODS: A multi-national, open-label, controlled, randomized, parallel-group, phase II pilot study was conducted in 20 centers in 7 countries. Cilengitide was administered at 600 mg/m(2 )twice weekly for 4 weeks per cycle and gemcitabine at 1000 mg/m(2 )for 3 weeks followed by a week of rest per cycle. The planned treatment period was 6 four-week cycles. The primary endpoint of the study was overall survival and the secondary endpoints were progression-free survival (PFS), response rate, quality of life (QoL), effects on biological markers of disease (CA 19.9) and angiogenesis (vascular endothelial growth factor and basic fibroblast growth factor), and safety. An ancillary study investigated the pharmacokinetics of both drugs in a subset of patients. RESULTS: Eighty-nine patients were randomized. The median overall survival was 6.7 months for Cilengitide and gemcitabine and 7.7 months for gemcitabine alone. The median PFS times were 3.6 months and 3.8 months, respectively. The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively. Changes in the levels of CA 19.9 went in line with the clinical course of the disease, but no apparent relationships were seen with the biological markers of angiogenesis. QoL and safety evaluations were comparable between treatment groups. Pharmacokinetic studies showed no influence of gemcitabine on the pharmacokinetic parameters of Cilengitide and vice versa. CONCLUSION: There were no clinically important differences observed regarding efficacy, safety and QoL between the groups. The observations lay in the range of other clinical studies in this setting. The combination regimen was well tolerated with no adverse effects on the safety, tolerability and pharmacokinetics of either agent